Proxalutamide for the treatment of COVID‐19 rebound following Paxlovid treatment: Report of four cases and review of the literature

BACKGROUND: The pandemic the coronavirus disease 2019 (COVID‐19) has created a global health crisis. Although Paxlovid is recommended for the early‐stage treatment of mild‐to‐moderate COVID‐19 in patients at increased risk of progression to severe COVID‐19, more and more cases are reported a COVID‐1...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Da‐Wei, Ju, Min‐Jie, Wang, Hao, Jia, Yi‐Chen, Wang, Xiao‐Dan, Fang, Hao, Fan, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220290/
https://www.ncbi.nlm.nih.gov/pubmed/37088868
http://dx.doi.org/10.1002/jcla.24880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10220290/
https://www.ncbi.nlm.nih.gov/pubmed/37088868
http://dx.doi.org/10.1002/jcla.24880

Ejemplares similares